Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 151.52B, Pfizer(PFE) trades at $26.60. The stock has a price-to-earnings ratio of 15.41 and currently yields dividends of 6.5%.
During the trading session on 2026-02-02, Pfizer(PFE) shares reached a daily high of $26.69 and a low of $26.11. At a current price of $26.60, the stock is +1.9% higher than the low and still -0.3% under the high.
Trading volume for Pfizer(PFE) stock has reached 52.13M, versus its average volume of 51.54M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Pfizer agreed to acquire obesity drug developer Metsera for $10b in cash, re-entering the weight loss market. The company outlined a larger R&D push in oncolog...
Drugmaker Pfizer (PFE) is set to report its Q4 earnings results on February 3 before the market opens. Analysts are expecting earnings per share to come in at $...
Pfizer Inc. (NYSE:PFE) will release earnings results for its fourth quarter, before the opening bell on Tuesday, Feb. 3. Analysts expect the New York-based com...
Analyst ratings
57%
of 28 ratingsMore PFE News
Pfizer agreed to acquire Metsera for $10 billion, aiming to expand into obesity and weight loss drugs. The company is reshaping its R&D focus toward metabolic...
Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting. Pfizer (PFE +1.26%) got a huge boost during the coronavirus...
In January 2026, Novavax announced a non-exclusive, worldwide license and option agreement granting Pfizer access to its Matrix-M adjuvant technology for vaccin...
Pfizer (PFE) is back in focus after two fresh pipeline updates: a non-exclusive Matrix M vaccine adjuvant licensing deal with Novavax and FDA Breakthrough Thera...
If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone, many investors are asking the same question right no...
Key Points The coronavirus contagion created a brilliant but relatively short-lived opportunity. R&D work that had been put on hold earlier during the COVID-1...
The Trump administration has announced the names of 15 drugs targeted for Medicare price negotiations for 2028. The new list of branded medications announced by...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.